Sotatercept
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sotatercept: From Pulmonary Arterial Hypertension to Acute Lymphoblastic Leukemia
One-Sentence Summary
Sotatercept is an activin receptor IIA-Fc fusion protein whose established approved indication is pulmonary arterial hypertension (PAH), as noted in the evidence pack’s own mechanistic notes. The TxGNN model predicts it may be effective for Acute Lymphoblastic Leukemia, but 0 clinical trials and 0 publications currently support this direction — the prediction rests on model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pulmonary arterial hypertension (PAH) — not from a Danish licence record (drug not marketed in Denmark); referenced only in the evidence pack’s mechanistic notes |
| Predicted New Indication | Acute Lymphoblastic Leukemia |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 (model prediction only, no trials or literature) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a data gap in this evidence pack). Based on the limited information present, Sotatercept is an Activin receptor IIA-Fc fusion protein (“ligand trap”) that captures Activin A/GDF11 and related TGF-β superfamily ligands; this pathway is known to regulate erythropoiesis and vascular remodeling, which underlies its approved use in pulmonary arterial hypertension.
The evidence pack’s own mechanistic rationale for Acute Lymphoblastic Leukemia describes the Activin/GDF signalling pathway as relevant to bone-marrow haematopoiesis (the same family target as luspatercept, used in MDS-related anaemia) but states explicitly that there is no direct evidence linking this pathway to ALL’s tumorigenic mechanism — the connection is characterised in the source data itself as “highly speculative with low biological plausibility.”
Because no clinical trials, ICTRP records, or literature exist for this drug-disease pair, the mechanistic rationale cannot currently be corroborated by any external evidence, and the prediction should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Denmark Market Information
Sotatercept currently holds no marketing authorisation in Denmark (0 licences on file; market status: Not marketed). No national (Laegemiddelstyrelsen) or centralised (EMA) authorisation records are available in this evidence pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication (Acute Lymphoblastic Leukemia) has zero supporting clinical trials or literature, an evidence level of L5, and the pack’s own mechanistic rationale rates the biological link as weak/speculative. Combined with the absence of a Danish marketing authorisation and missing MOA/safety data, this candidate does not meet the threshold to proceed.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data (currently a Blocking/High-severity data gap)
- TFDA/SmPC-sourced warnings and contraindications (currently a Blocking data gap, required for S1 safety screening)
- Preclinical or mechanistic studies directly linking Activin/GDF signalling to ALL pathogenesis
- Clarification of Denmark regulatory pathway, given the drug is not currently marketed there
Note: This evidence pack lists several other top-ranked candidates with comparably weak, evidence-free support — severe nonproliferative diabetic retinopathy, diabetic retinopathy, drug-induced osteoporosis, and diabetic cataract (all L5, Hold) — should a broader review of Sotatercept’s repurposing landscape be needed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.